Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Preferred Stock Liabilities (2023 - 2024)

Zenas BioPharma has reported Preferred Stock Liabilities over the past 2 years, most recently at $956000.0 for Q2 2024.

  • Quarterly results put Preferred Stock Liabilities at $956000.0 for Q2 2024, changed N/A from a year ago — trailing twelve months through Jun 2024 was $956000.0 (changed N/A YoY), and the annual figure for FY2023 was $250.1 million, changed.
  • Preferred Stock Liabilities for Q2 2024 was $956000.0 at Zenas BioPharma, down from $193.3 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for ZBIO hit a ceiling of $250.1 million in Q4 2023 and a floor of $956000.0 in Q3 2023.